Skip to main content

Table 1 Demographics and clinical characteristics of sample, stratified by iron dosing (N=48,050)

From: Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study

Characteristics, mean (SD) or% Bolus (13.9%) Maintenance (49.3%) Non-user (36.8%)
Demographic    
  Age, y 60.1 (15.3) 61.4 (15.1) 61.4 (15.1)
  Female 45.8 45.1 45.3
  Race: White 38.2 40.1 37.3
     Black 56.7 54.1 56.8
     Other 5.1 5.7 5.9
  Region: Midwest 6.2 11.0 8.1
      Northeast 80.6 84.3 78.6
      South 10.6 2.8 9.6
      West 1.8 1.4 3.0
Clinical    
  Vintage, y 4.8 (4.7) 5.1 (5.0) 5.8 (5.5)
  Body Mass Index 32.8 (23.5) 33.9 (29.8) 31.6 (24.7)
  Catheter Use 21.6 19.5 17.2
Laboratory and Anemia Management Variables    
  Albumin at baseline 3.84 (0.41) 3.91 (0.37) 3.93 (0.38)
  Hemoglobin at baseline 11.5 (1.4) 12.0 (1.3) 11.9 (1.4)
  Index TSAT 23.7 (9.5) 31.4 (10.9) 35.8 (14.3)
  Ferritin at baseline 625 (479) 745 (536) 862 (588)
  Iron (mg) at baseline 314 (316) 279 (214) 109 (241)
  Iron (mg) during exposure 700 (291) 227 (118) 0.0 (0.0)
  EPO at baseline (1000U) 111 (98) 75.3 (78.3) 62.0 (74.0)
  EPO during exposure (1000U) 113 (100) 73.1 (77.0) 63.0 (73.9)
Comorbidities    
   Hospital days in last month 1.0 (2.3) 0.6 (1.9) 0.5 (1.8)
   Infection in last month 17.5 12.6 10.4
   Infection in last 6 mos. Pneumonia 16.7 12.8 11.5
      Sepsis 23.5 19.0 14.9
      Vascular access 15.0 10.1 9.2
   Diabetes 67.5 64.1 60.7
   Ischemic stroke 16.7 12.9 12.5
   Myocardial Infarction 6.2 4.4 4.0
   COPD, Asthma 24.4 20.0 18.0
   Cancer 12.1 10.9 11.7
   GI bleeding 9.5 6.1 5.2